许景艳 - 中国药科大学 - 基础医学与临床药学学院

个人简介

许景艳，女，1967年出生，医学博士，主任医师，硕士生导师。1990年南京医科大学临床医学专业毕业，同年至南京鼓楼医院血液科工作至今，具有28年的血液病临床、教学和科研工作经验。南京大学附属南京鼓楼医院血液科淋巴瘤亚专科负责人，江苏省“六大人才高峰”高层次人才培养对象。江苏省医学会血液分会淋巴瘤骨髓瘤学组委员、江苏省抗癌协会淋巴瘤专业学组委员、中华医学会内科学分会血栓工作委员会委员、美国血液学会会员、江苏省抗癌协会白血病/MDS专业学组委员、江苏省研究型医院学会白血病/MDS学组常委、世界中医药学会联合会血液病专业委员会理事、江苏省医学会医学鉴定常任专家。

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1、Hui Li1, Xiaoxuan Yu1, Xiao Liu, Po Hu, Le Shen, Yuxin Zhou, Yu Zhu, Zhiyu Li, Hui Hui, Qinglong Guo*, Jingyan Xu*. Wogonoside induces depalmitoylation and translocation of PLSCR1 and N-RAS in primary acute myeloid leukaemia cells. Journal of Cellular and Molecular Medicine. 2018 Apr; 22(4):2117-2130. (IF 2016= 4.499) 2、Hui Hui1, Xiaoxiao Zhang1, Hui Li, Xiao Liu, Le Shen, Yu Zhu, Jingyan Xu*, Qinglong Guo*, Na Lu*. Oroxylin A, a natural anticancer flavonoid compound, induces differentiation of t(8;21) positive Kasumi 1 and primary acute myeloid leukemia cells. Journal of cancer research and clinical oncology. 2016 Jul;142(7):1449-59. (IF 2016 =3.5) 3、Jing Wang, Biao Zhang, Bing Chen, Rong-Fu Zhou, Qi-Guo Zhang, Juan Li, Yong-Gong Yang, Min Zhou, Xiao-Yan Shao, Yong Xu, Xi-Hui Xu, Jian Ouyang, Jingyan Xu* & Qing Ye*. JAK2, MPL, and CALR mutations in Chinese Han patients with essential thrombocythemia. Hematology, 2017, 22:3, 145-148. (IF 2017 =1.314) 4、Jing-Yan Xu, Yun-Yu Sun, Min Zhou, Jing Wang, Qi-Guo Zhang, Xi-Hui Xu , Hui Zeng, Jian Ouyang. Methylenetetrahydrofolate reductase gene polymorphisms association with the risk of follicular lymphoma: a meta-analysis. Tumor Biology (2013) 34:1467–1471. (IF 2013 =2.84) 5、Jingyan Xu, Min Zhou, Jian Ouyang, Jing Wang, Qiguo Zhang, Yong Xu, Yueyi Xu, Qian Zhang, Xihui Xu, Hui Zeng. Gambogic acid induces mitochondria-dependent apoptosis by modulation of Bcl-2 and Bax in mantle cell lymphoma JeKo-1 cells. Chinese Journal of Cancer Research. 2013;25(2):183-191. (IF 2013 =0.932) 6、Yanting Wen*, Jingyan Xu*, Xiaodong Ma, Qian Gao. High-dose erythropoietin in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized controlled trials, American Journal of Cardiovascular Drugs (2013) Dec;13(6):435-42. (IF 2013 =2.48) 7、Jing Wang*, Min Zhou*, Jing-Yan Xu*, Yong-Gong Yang, Qi-Guo Zhang, Rong-Fu Zhou, Bing Chen, Jian Ouyang and Cuiping Li. MYC and BCL-2 adjusted-International Prognostic Index (A-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Histology and histopathology. 2016:31:285-292. (IF 2016=2.025) 8、Jing Wang,* Min Zhou,* Jing-Yan Xu,* Bing Chen, and Jian Ouyang. Combination of Bcl-2 and MYC protein expression improves high-risk stratification in diffuse large B-cell lymphoma. OncoTargets and Therapy, 2015, 8:2645-50. (IF 2015=2.272) 9、Jing Wang*, Min Zhou*, Jing-Yan Xu*, Yong-Gong Yang, Qi-Guo Zhang, Rong-Fu Zhou, Bing Chen, and Jian Ouyang. Prognostic role of pretreatment neutrophillymphocyte ratio in patients with diffuse large B-cell lymphoma treated with RCHOP. Medicine, (2016) 95:38(e4893). (IF 2016 =1.803) 10、MIN LI*, LICHAN XIAO*, JINGYAN XU*, RUN ZHANG, JINGJING GUO, JUSTIN OLSON, YUJIE WU, JIANYONG LI, CHUNHUA SONG, and ZHENG GE. Co existence of PHF6 and NOTCH1 mutations in adult T-cell acute lymphoblastic leukemia. ONCOLOGY LETTERS 2016 Jul; 12(1): 16–22. (IF 2016 =1.3)